Kissei Pharmaceutical Co., Ltd. (KSPHF)

Kissei Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	89,357	88,330	75,579	67,493	65,381	69,044
Revenue Growth (YoY)	15.40%	16.87%	11.98%	3.23%	-5.30%	9.19%
Cost of Revenue	45,093	44,265	38,238	35,118	34,143	36,321
Gross Profit	44,264	44,065	37,341	32,375	31,238	32,723
Selling, General & Admin	38,539	22,179	20,790	20,289	19,923	19,607
Research & Development	-	12,889	9,474	10,391	10,363	9,626
Other Operating Expenses	-	129	143	149	137	149
Operating Expenses	38,539	38,291	33,324	33,518	32,640	31,217
Operating Income	5,725	5,774	4,017	-1,143	-1,402	1,506
Interest Expense	-23	-21	-18	-20	-23	-23
Interest & Investment Income	1,490	1,449	1,318	1,402	1,586	1,272
Currency Exchange Gain (Loss)	-241	-229	-103	186	-60	-130
Other Non Operating Income (Expenses)	33	29	35	57	280	131
EBT Excluding Unusual Items	6,984	7,002	5,249	482	381	2,756
Gain (Loss) on Sale of Investments	12,102	11,719	9,119	13,133	16,161	4,727
Gain (Loss) on Sale of Assets	-203	-215	80	63	-35	-10
Asset Writedown	-2,767	-2,895	-	-	-	-
Other Unusual Items	-280	-2	-1	1	-1	3
Pretax Income	15,836	15,609	14,447	13,679	16,506	7,476
Income Tax Expense	3,446	3,634	3,159	3,046	3,475	2,098
Earnings From Continuing Operations	12,390	11,975	11,288	10,633	13,031	5,378
Minority Interest in Earnings	-16	-14	-128	-105	-110	-93
Net Income	12,374	11,961	11,160	10,528	12,921	5,285
Net Income to Common	12,374	11,961	11,160	10,528	12,921	5,285
Net Income Growth	3.11%	7.18%	6.00%	-18.52%	144.48%	87.61%
Shares Outstanding (Basic)	43	44	45	46	46	47
Shares Outstanding (Diluted)	43	44	45	46	46	47
Shares Change (YoY)	-3.93%	-3.62%	-1.86%	-	-1.18%	-0.11%
EPS (Basic)	287.48	274.20	246.58	228.30	280.19	113.25
EPS (Diluted)	287.48	274.20	246.58	228.30	280.19	113.25
EPS Growth	7.32%	11.20%	8.01%	-18.52%	147.41%	87.81%
Free Cash Flow	-	2,014	-2,878	-8,782	44	-3,473
Free Cash Flow Per Share	-	46.17	-63.59	-190.44	0.95	-74.42
Dividend Per Share	100.000	100.000	82.000	80.000	56.000	54.000
Dividend Growth	21.95%	21.95%	2.50%	42.86%	3.70%	3.85%
Gross Margin	49.54%	49.89%	49.41%	47.97%	47.78%	47.39%
Operating Margin	6.41%	6.54%	5.32%	-1.69%	-2.14%	2.18%
Profit Margin	13.85%	13.54%	14.77%	15.60%	19.76%	7.66%
Free Cash Flow Margin	-	2.28%	-3.81%	-13.01%	0.07%	-5.03%
EBITDA	10,430	10,389	8,271	2,966	2,328	4,654
EBITDA Margin	11.67%	11.76%	10.94%	4.40%	3.56%	6.74%
D&A For EBITDA	4,705	4,615	4,254	4,109	3,730	3,148
EBIT	5,725	5,774	4,017	-1,143	-1,402	1,506
EBIT Margin	6.41%	6.54%	5.32%	-1.69%	-2.14%	2.18%
Effective Tax Rate	21.76%	23.28%	21.87%	22.27%	21.05%	28.06%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.